Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials

Peer Review reports

Original Submission
29 Dec 2016	Submitted	Original manuscript
17 Jan 2017	Reviewed	Reviewer Report - Emanuel Raschi
24 Jan 2017	Reviewed	Reviewer Report - Elisabetta Poluzzi
3 Feb 2017	Author responded	Author comments - Pravesh Bundhun
Resubmission - Version 2
3 Feb 2017	Submitted	Manuscript version 2
Publishing
28 Feb 2017	Editorially accepted
16 Apr 2017	Article published	10.1186/s40360-017-0126-9

Back to article page